Bristol Myers Squibb (BMY): Bayer enrolls first phase-3 patients for...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	789
Posts	118230
Boards Moderated	17
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 1102

Wednesday, 02/08/2023 7:50:17 AM

Wednesday, February 08, 2023 7:50:17 AM

Bayer enrolls first phase-3 patients for FXIa inhibitor, Asundexian:

https://www.businesswire.com/news/home/20230208005322/en

• The OCEANIC program will investigate the efficacy and safety of asundexian (BAY2433334) in the prevention of stroke in patients with atrial fibrillation and also patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA)
2
• OCEANIC-AF and OCEANIC-STROKE are expected to enroll more than 27,000 patients in over 40 countries

Bayer’s competition in this arena is BMY/JNJ’s Milvexian (#msg-169818942, #msg-169841711), which is awaiting the start of phase-3.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”